锚定新质生产力昌平合成生物产业再提速

Core Viewpoint - The rapid growth of Weiyuan Synthesis, supported by comprehensive policies and funding from Changping District, highlights the district's commitment to becoming a hub for synthetic biology manufacturing and innovation [1][2]. Group 1: Company Development - Weiyuan Synthesis has expanded from 3 to over 400 employees, with a recent completion of nearly 300 million yuan in equity financing to accelerate the development of methanol-based bio-manufacturing products [1]. - The company has received 80 million yuan in investment from a municipal health fund, showcasing strong governmental support for its growth [1]. Group 2: Industry Ecosystem - Changping District has established 146 synthetic biology manufacturing companies and 16 common technology service platforms, with 56 new enterprises registered since 2024 and a total registered capital exceeding 300 million yuan [2]. - The district has been recognized as the first national-level characteristic industrial cluster in synthetic biology manufacturing, enhancing its brand visibility and demonstrating its role as a future industrial growth pole [1][2]. Group 3: Innovation and Technology - Significant original achievements have emerged from Changping, including the selection of a biological synthesis technology for 2-hydroxyhexanedioic acid as a major scientific achievement for the 2025 Zhongguancun Forum [3]. - Weiyuan Synthesis has received approval for the production of several products, including alulose and new yeast proteins, with multiple products accelerating through the approval process [3]. Group 4: Future Plans - Future City Group aims to enhance the innovation center's influence, attract quality teams, and promote technology transfer, with a goal of landing 10 landmark projects by 2026 [4]. - The establishment of a pilot base for synthetic biology manufacturing is planned to address challenges in technology transfer and further solidify the region's position in the industry [4].